Btim, I agree, especially since Dr West was once CEO and Chief Scientific Officer of ACT, of course Dr Lanza would remain as Chief Scientic Officer, and Dr West would run the rest of the company. I also like the idea that BTX bought Geron's spinal cord injury program.
Yeah, hope they go for it and merge, because God only knows how much ACT needs an infusion of hope.
How much trouble do you think ACTC will have raising funds once the Phase 2A results are released next spring? The answer is NONE, and come 2015 they will be in a position to buy BTX if there was any reason to?
I disagree. ACTC would start over, wipe out their debt, have along with BTX have multiple Renevia products coming out in the next two years. Products will include, blood disorders, stroke, brain, and heart regen....as well as cosmetic surgery(which will be the first). Biotime has ip for adipose stem cells, and using ECM hydrogels and of course ACTC's ips iip, they can reprogram a patients cells.
Interesting....This would reunite ACTC with their ACTcellerate IP(now PureStem), and BTX would own the IPS IP which Dr. West helped to create while at ACTC.
Biotime Recyte has a lot to offer, including their Renevia product that uses ECM, which gets a CE mark in Europe in a few months.
ReCyte Therapeutics, Inc. is a regenerative medicine company focused on repair of vascular disorders, including both age-related diseases and injuries. The company was founded in January 2011 as a subsidiary of BioTime, Inc. with a significant investment by private shareholders and by BioTime. Our therapeutic products are derived from human stem cells in vitro, including from embryonic and induced pluripotent stem cell sources. In composition, these therapeutics are designed to be either cellular or totally acellular for specific uses, the latter representing an entirely new class of stem cell-derived therapeutics.